SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " clinical " 972 found 🔀 AI-powered Shuffle
Signant Health, Lothar Medical Plan Integrated Respiratory Trial Device
Signant Health and Lothar Medical plan integrated respiratory trial device combining spirometry, oscillometry, and FeNO measurement into a single platform.
How Often You Exercise May Matter More Than How Hard You Work Out for Mental Health
When it comes to reducing the risk of depression and anxiety, how often students exercise may matter more than how hard they push themselves. A large Norwegian study found that students who exercised infrequently were more likely to develop clinically defined depression, anxiety, or another common mental disorder over the following year. How often they
Scientists find a weak spot in one of the deadliest brain cancers
Researchers may have found a new way to weaken glioblastoma’s defenses against treatment. Blocking a protein called SET prevented tumors from forming in preclinical models, while targeting related proteins made cancer cells more vulnerable to radiation. The strategy works by restoring activity of PP2A, an enzyme that glioblastoma cells appear to suppress. Human testing will be needed to determine whether the approach is safe and effective.
RB Leipzig’s Winning Start Comes Crashing Down in Bremen
Werder Bremen dismantled Leipzig's early-season momentum with a clinical counter-attacking display, exposing defensive vulnerabilities and grounding Martín Demichelis’ squad after their dominant opening weekend performance.
Signant Health and Lothar Medical Sign Letter of Intent to Commercialize ALDS PRO for Clinical Trials
Signant Health, a leading provider of evidence generation solutions for clinical trials, and Lothar Medical today announced that they have signed a letter of intent outlining a planned strategic collaboration to bring Lothar Medical's next-generation pulmonary function technology to the global clinical trial market.
The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.
Nuclear medicine physician-scientist Dr. Amir Iravani joins UCLA Health to lead Theranostics Program
Dr. Amir Iravani will serve as director of the Theranostics Program and vice chair of clinical research in the department of nuclear medicine and theranostics.
Judi Health Taps Color Health, WellTheory, Cylinder for Clinical Ecosystem
Judi Health expanded its healthcare network to offer specialized virtual care for cancer, autoimmune and GI conditions while helping employers reduce overall healthcare costs.
Nuclear medicine physician-scientist Dr. Amir Iravani joins UCLA Health to lead Theranostics Program
Iravani will help advance the integration of theranostics into cancer care, expand clinical trials and research opportunities and develop new collaborations.
ChatGPT for Healthcare unveils Epic integration as part of data consolidation strategy
In addition to providing Epic users with access to the popular LLM, OpenAI said all clinicians that use its platform will be able to access public databases, including ClinicalTrials.gov and PubMed, with the proper plug-ins in place.
AI pinpoints radiology residents’ educational gaps, helping expand personalized training
New research details how artificial intelligence can be harnessed to improve radiology resident education by identifying shortfalls in clinical exposure and reinforcing missed concepts.
Childhood cancer patients and families target of new Ohio Department of Health program
By extending its existing Complex Medical Help Program, the Ohio Department of Health will add new staff to connect families with resources, from Medicaid coverage to doctors to clinical trials.
Why health equity is now a business imperative in cardiology
For health systems under value-based care payment initiatives, there a direct financial incentive to invest in programs that improve access and outcomes among underserved populations. Cardiologist Dipti Itchhaporia, MD, shared her thoughts on this important topic.
Kiggans, Underwood Recognize September 1st-8th as National Clinical Nurse Specialist Week
WASHINGTON, D.C. — Today, Congresswoman Jen Kiggans (VA-02) and Congresswoman Lauren Underwood (IL-14) introduced a resolution to recognize the first...
Statement by Chief Pentagon Spokesman, Sean Parnell, on the Clinical G
The War Department remains focused on building and maintaining a ready, lethal fighting force prepared to dominate the battlefield and achieve peace through strength.
Neuropsychologist finds gaps between treatment and science of ALS, dementia in her own family
For A. Campbell Sullivan, PsyD, this time it's personal. As a neuropsychologist and clinical associate professor of neurology at the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases ...
How Richmond became a hub for complex medical care
The most complicated medical cases can require more than standard care, from specialized clinical teams to research-informed treatment options.
UT Health San Antonio neuropsychologist finds gaps between treatment and science of ALS, dementia in her own family
As a neuropsychologist and clinical associate professor of neurology at the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio, A. Campbell Sullivan, PsyD, is on the front lines daily of groundbreaking research and patient care in frontotemporal dementia and other neurodegenerative disorders.
Millions get wrong genetic test, study finds
A study shows current testing is providing false reassurance about genetic disposition for a rare life-threatening drug reaction.
UT Health San Antonio neuropsychologist finds gaps between treatment and science of ALS, dementia in her own family
Her journal article urges more support for those facing inherited neurodegenerative diseases Contact for media: Steven Lee, (210) 450-3823, lees22@uthscsa.edu SAN ANTONIO, Sept. 2, 2026 – For A. Campbell Sullivan, PsyD, this time it’s personal. As a neuropsychologist and clinical associate professor of neurology at the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health […]
UT Health San Antonio neuropsychologist finds gaps between treatment and science of ALS, dementia in her own family
Her journal article urges more support for those facing inherited neurodegenerative diseases Contact for media: Steven Lee, (210) 450-3823, lees22@uthscsa.edu SAN ANTONIO, Sept. 2, 2026 – For A. Campbell Sullivan, PsyD, this time it’s personal. As a neuropsychologist and clinical associate professor of neurology at the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health […]
August Monthly Review: ChatGPT In Epic
Death, taxes, another frontier lab healthcare launch inspiring truly insane LinkedIn takes. As much as I want to stay away, I repeatedly am the crewman unplugging his ears whenever we pass these sirens. So it’s not the first and probably not the last time we dial up the typewriter rather than tie ourselves to the mast. The full blow-by-blow timeline: Health API Guy is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe The End of the Standalone PHR (Jan 8): ChatGPT Health arrives for consumers, at the time powered by b.well. I was bullish on the approach in that the best way for the PHR to finally solve distribution was to meet consumers were they already are (i.e. When Horizontal Meets Healthcare (Jan 9): OpenAI for Healthcare puts out the shingle for enterprises, with SharePoint ingestion standing in for the EHR integration the product actually needed. Another One: Anthropic’s Healthcare Debut (Jan 16): Claude's version, on HealthEx rails instead of b.well, with Agent Skills for FHIR development as the one true vertical-specific investment. ChatGPT for Clinicians: The Trap Sprung (Apr 24): OpenAI filled in the missing GTM middle with a free product for verified clinicians, effectively peeling the enterprise wrapper off ChatGPT for Healthcare and taking the PLG fight directly to OpenEvidence. OpenAI’s Second Attempt at Health (Jul 31): a relaunch of their patient specific app, now branded Health in ChatGPT, where the privacy partition came out, the connectors thinned, and b.well disappeared in favor of first-party FHIR work against a smaller network Beyond a Shingle So what was announced now? Today, we’re introducing a new electronic health record integration that brings authorized patient context from Epic into ChatGPT for Healthcare, along with the Healthcare Public Data plugin for direct, structured access to official healthcare datasets like PubMed, DailyMed, and CMS Coverage. Together, these capabilities bring ChatGPT closer to the systems and sources healthcare teams trust, while supporting the controls and compliance healthcare work requires. The core portfolio is unchanged from prior announcements we delineated and discussed (aside from the relaunch of patient-facing). Since trade publications still seem to be confusing them by using the wrong names: Enterprise sales motion: ChatGPT for Healthcare Protecting their core product / PLG: ChatGPT for Clinicians Consumer/patient-facing product: Health in ChatGPT So really, this is a feature release (specifically for ChatGPT for Healthcare when it comes to EHR integration). What’s cool about it, though, is that we are moving beyond just putting out a shingle. Everything in the January enterprise launch was horizontalizable: Horizontal tech companies thus generally start verticalization with their “putting out a shingle phase”. Telling the world you’re open for business as a horizontal tech company reliably attracts early inbound interest from buyers who are already trying to force-fit horizontal tools into domain-specific workflows and are eager for any signal that the vendor intends to support their use case more directly. Nothing was really vertical specific, which is exactly what you'd expect from the ultimate hypergrowth horizontal company dipping their toes into specific industries. But eventually you have to stop changing the sign on the door and start changing the product. Can you guess where the horizontal product was going to run out of road? This is the core dilemma writ large: verticalization requires differentiation, while scale economics of consumer and horizontal push toward unification. I’ve buried the lede so deep here it will be painful to some readers, but what should be shocking to no one is that my perspective is that EHR integration is the only path that meaningfully resolves this tension for ChatGPT for Healthcare. Integration with Microsoft Sharepoint is fine, but it is categorically insufficient for any product that hopes to influence clinical decision-making. SMART Money Well here we are, eight months later! Real vertical investment has begun, which surprised a few people. One friend in the industry messaged me: “Absolutely no way Epic gave ChatGPT API access.” Looking forensically at the announcements, the integration is notably read-only across appointment notes, laboratory results, medications, and specialist documentation. So while I’m not a betting man, I'd wager the house this is a SMART on FHIR launch: That sounds a lot like USCDI! The recommended path for the workflow they outline would be SMART on FHIR Their Health AI lead’s post is evocative of both standalone and EHR launch SMART, which another termed “ChartGPT” and “EHR Plugin” The implementation burden for SMART on FHIR is the lowest of the available integrative paths This is the team who literally did patient-facing SMART on FHIR with Epic last month Most importantly, if you’re a horizontal company, you generally still haven’t taken the full plunge and thus (overly) value reusability. SMART on FHIR is the logical compromise: healthcare-specific enough to matter, but standardized enough to reuse. Nobody Asked Judy Another friend asked “I thought they had to go to each health system, or did they go direct to Epic and now health systems opt in?” Given the trust paradigms in healthcare, this functionally cannot be Epic hoovering up all the data for OpenAI and shoving ChatGPT in their customers’ faces (or they would revolt). However, I do believe the aforementioned terrible coverage by TechCrunch and other outlets is probably responsible for that question, given the 325 million reference. When using FHIR as a business associate to an Epic customer, there is no EHR gatekeeping to speak of, as that isn’t how fhir.epic.com works: You register an app You pick your APIs You test against the sandbox APIs You list as “Ready for Production” Hospitals pick your app You test and go live with them Bluntly, nobody had to say yes or no in Verona (nor were they given the chance). Vendor Services (their next developer tier up that I doubt OpenAI is using quite yet in this initial release) certainly has contractual paperwork that some resent, but even there, the twin pressures of mounting antitrust and information blocking make outright gatekeeping increasingly fraught. My friend’s sentiment is, to me, representative of a broader industry neurosis, perhaps a sort of scar tissue of prior eras: people assume the gate is still there and never actually try the door. There are certainly other ways Epic (and any EHR) can put its thumb on the scale, but they are not so dumb as to stand in front of a federally mandated API and play bouncer at this exact moment in time. So I think they can and probably should go deeper, as this release is at best parity and at worst behind vertical-specific competition. OpenEvidence did a basic SMART launch with Sutter Health in February, allowing for more convenient evidence search by providers. They then add patient-context (the equivalent SMART on FHIR flow to what we see here) when Cedars-Sinai went enterprise-wide in May. UpToDate has four distinct applications across deeper workflows like patient engagement listed in Epic Showroom and announced a partnership with Epic to power Art at UGM Abridge and other ambient scribes have invested deeply into the deepest bidirectional clinical copilot workflow with integrations well beyond SMART on FHIR. In that light, the “Who is OpenAI primarily targeting here?” is clear. This release brings them into striking distance of OpenEvidence, but not the others quite yet. They are the only one of the three you can reach without building something truly Epic-specific. When will they go further? Competition is a great motivator to overcome the horizontal demons and start building things that can’t be reused: not across industries, not across EHRs, maybe not past the customer you built them for. That’s the price of actually verticalizing. The question is if and when OpenAI will be willing to pay it. Month in Review Here is the monthly review. As a reminder, this is a regular round-up of the month’s posts and other content to surface things you may have missed across regulation, litigation, interoperability, and beyond. AI assistance is used in these bullet summaries so I can focus on articles. Articles Published: None this month Video Content: The Information Exchange: Standards-based Thruple Edition (Aug 14): Back to school for us too, with Brad reporting in from the CMS Health Tech Ecosystem’s one year anniversary in DC. We get into the January CMS-0057 deadline, the fall rulemaking reading list, and why enrollment still keeps most apps off FHIR. The Information Exchange: Epic Dúnadan Edition (Aug 25): A UGM roundup with Ryan Brickner joining for the first time to check our takes against what the building actually thinks. Rangers, Ergo sitting on top of EHI, and a down-market lineup that needs some cuts. Regulatory: Stacked Deck, Bad Hand (Aug 05): ONC’s website refresh took the entire HIT Policy Committee record with it, so I rebuilt the archive and went looking for the regulatory capture story everyone assumes is buried in there. Stacking the deck and winning the hand turn out to be very different things. The Sixth Generation of Patient Access (Aug 19): A quick catalog of the five generations of patient access we’ve layered on since HIPAA, and the two candidates now competing to be the sixth. One is planned. The other is the market routing around the plan entirely. Court cases: Three Cases Walk Into a Docket (Aug 06): Two surprise settlements cleared the board in a single week, and then Judge Maddox dropped ninety-four pages on Vyne v. Henry Schein. The sleeper is a DMCA holding that makes direct-to-database a considerably riskier business model. Epic v. Health Gorilla: Into the MDL (Aug 10): Nine class actions are headed to Miami, and the Panel signaled it wants to bring the case that spawned them along too. That would leave Epic arguing the requests were obviously fraudulent in one courtroom and unknowable in the other. Amazon v. Perplexity: Agents Are Legalized! (Aug 11): The Ninth Circuit vacated the injunction against Comet, holding that the user is the one accessing the servers rather than the company that built the agent. A real win for agentic access, and a much narrower one than the headline suggests. Veeva v. Epic: Come At Me, Bro (Aug 26): Epic’s response brief wants the dismissal affirmed and, unusually, wants the opinion published as precedent. Buried in it is Epic’s own description of what its non-competes actually prohibit, which current and former employees should read closely. EHRs: The Contract Epic Would Never Sign Today (Aug 04): A 1999 SEC exhibit catches Epic licensing nearly its entire product line, Tapestry included, to the company that became TriZetto. The marketing services menu attached to it is the part that will make you blink. Forecast from Verona (Aug 07): The Epic Almanac makes one argument six different ways: the AI is only as good as the networks behind it. Emmie headlines, Art’s context stack is the most ambitious part, and Penny finally gets an autonomous coding date on the calendar. Works With Epic MyChart (Aug 17): Epic’s first new Showroom category since the death of Workshop certifies hardware instead of software, badge on the box and all. Made for iPhone, but for blood pressure cuffs, and rough news for anyone selling the RPM stack sitting in between. UGM Hot Takes 2026 (Aug 20): Everyone else covered the AI announcements, so I went after Savvy deleting the payment gateway, Rangers as Boost with the timer removed, and a down-market lineup with too many entries. Plus the Health Grid tidbits I cannot help myself on. MyChart Central Grows Up (Aug 24): Device data and Emmie turn Epic’s identity hub into a full consumer platform, which is both a logical answer to ChatGPT and a bit of a mistake. It also happens to be the best scraping target Epic has ever shipped. Industry Analysis: The Wrong Yardstick (Aug 12): Vertical software keeps getting judged against Superhuman and Notion, which is the wrong bar entirely. Your user is comparing your product to a whiteboard and forty phone calls before lunch. Primitives vs. Abstractions (Aug 27): Developers want building blocks, systems of record prefer to hand out business logic, and both sides have a real case. There’s no test from the outside that separates the engineering reason from the competitive one, which is why this keeps ending up in court. Cross-industry Comparisons: The Two Kinds of Platform Power (Aug 18): Attention power and record power are different problems that keep getting handed the same regulatory toolkit. Congress’s latest swing at Big Tech shows both what’s possible and where it falls apart. The Dogs of (Platform) War (Aug 21): A CourtListener alert turned up a property management fight with healthcare’s exact shape and none of the Cures Act. Shell prospects, ghost accounts, a notetaker bot that came back to haunt someone, and a lawyer arguing both sides of the same theory in two states. Fractals All the Way Down (Aug 31): Yardi dominates property management right up until you zoom into one segment, where AppFolio owns it outright and Yardi doesn’t appear at all. Where you draw the line around a B2B software market is about to decide an awful lot of cases. Other News: If Judy Had the Courage (Aug 13): A short eulogy for the era when software was allowed to look insane: WinAMP, bold colors, and everything the grey chatbot era has taken from us. External Media: Portland Monthly Health Tech Meetup: Erin O’Brien channeled my own feelings - maybe it’s just because it’s August and beautiful, but the monthly edition of the PDX Health community meetup was a ripper. Make sure to reach out if interested to join for the next one. STAT’s Coverage of Epic This Month: Brittany Trang of STAT did a fantastic job of breaking the FTC investigation that’s been lurking, as well as UGM related coverage, so I had to give her her wish of a meme. Fall Conferences: I’m pumped to be kicking off my fall conference season in NYC at Nabla Accelerate next month, which Chrissy provided the link to apply for. Here’s the rest of my schedule in case you want to meet up: Commonwell (Redwood Shores, CA): Oct 13-14 Open@Epic (Madison, WI): Oct 21-22 eHealthExchange (Austin, TX): Oct 27 Sequoia Project (Austin, TX): Oct 28-29 HLTH (Vegas): Nov 15-18 RSNA (Chicago): Nov 29-Dec 3 Posts I Liked: HTI-6 Should Unbundle API Certification: Josh Mandel makes the case that HTI-6 should split (g)(10) into separate authorization and data certifications, so a PACS or a genomics platform can certify only the role it actually performs. Imaging is the urgent example, but the structure solves a much bigger problem. On implementing ePrior Auth with Epic: Scott Rossignol’s field notes from a live ePrior Auth build on Epic, including the two app registrations nobody warns you about and the CPT mapping problem waiting at the end. CMS-0057 implementations are going to be such a beast. Healthcare point solutions are starting to look a lot like streaming services: Spencer Dorn runs the cable-to-streaming arc against health IT and lands squarely on the bundling half of the cycle. Bundling can be good! It can also be bad! Life is nuanced. Health API Guy is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe
Women's health
The European Medicines Agency (EMA) works to ensure that the needs of women are considered throughout the development, evaluation and use of medicines in the European Union (EU). This includes promoting appropriate representation in clinical research, providing guidance to medicine developers, improving knowledge on medicine use during pregnancy and breastfeeding, and generating real world evidence on women's health.
ChatGPT for Healthcare unveils new integrations with Epic, public health data sources
OpenAI is expanding ChatGPT's healthcare capabilities with new integrations that connect it more directly with clinical workflows and public healthcare sources. | OpenAI is expanding ChatGPT's healthcare capabilities with new integrations that connect it more directly with clinical workflows and public healthcare sources.
Aficamten shows potential to be first FDA-approved treatment for nonobstructive HCM
New data presented at ESC Congress 2026 represent a huge breakthrough for patients with nonobstructive HCM. "For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease," one researcher explained.
Tulane Ventures brings behavioral health company to New Orleans
Tulane Ventures has invested $250,000 in Cabana, a behavioral health platform co-founded by a Tulane alumnus, as part of a $1 million seed round that also includes 1834 Ventures.Cabana combines clinical care, community groups and tech-enabled support to embed behavioral health support — outside of medical appointments — in the lives of patients battling physical ailments.
Global Markets and Technologies for Electronic Health Records to Reach $52.2 Billion by 2030, Driven by Rising Chronic Disease Burden and Digital Health Adoption
“The global EHR market is projected to grow from $36.5 billion in 2025 to $52.2 billion by 2030 at a 7.4% CAGR as healthcare providers accelerate cloud deployment, interoperability and AI-enabled clinical workflows.”Boston, Aug. 31, 2026 (GLOBE NEWSWIRE) -- The global market for electronic health records (EHR) is projected to expand from $34.2 billion in 2023 to $52.2 billion by 2030, at a compound annual growth rate (CAGR) of 7.4% during 2025–2030, according to the BCC Research report Global Ma
After a rough stretch, mRNA gets a boost
With clinical success on a personalized mRNA vaccine for melanoma, experts are hoping for a more stable future for the technology in other areas.
FDA alerts patients after multiple complaints at West Coast imaging center
“Some clinical image quality deficiencies were severe,” the agency said, adding that the center is now required to submit an “extensive corrective action plan to the ACR.”
Scottie Scheffler polishes off Tour Championship in clinical fashion
Scottie Scheffler put a bow on his 2026 season in a way he does best, outlasting his peers and raising the trophy at the Tour Championship.
Experts weigh in on Lindsay Clancy's mental health defense and possible verdicts
Legal expert Kelly Hyman and licensed clinical psychologist Dr. Sabrina Romanoff analyze Lindsay Clancy's mental health defense and the charges facing the jury on 'Fox News Live.'
Clinical trial participation playing key role in advancing science
Clinical trials, whether for new cancer treatments or simple lifestyle interventions, are based on foundational science and lots of planning.
Keto diet cut liver fat by 67% in a clinical trial
A ketogenic diet outperformed Mediterranean and low-fat diets in several measures of metabolic health during a clinical trial involving people with obesity, prediabetes, and fatty liver disease. All three groups lost about 10% of their body weight, but keto reduced liver fat by 67%, compared with 45% for the other diets. About half of the keto group also no longer qualified as having prediabetes after four to five months.
In Southeast Minnesota, clinical trial participation plays a key role in advancing science
Clinical trials, whether for new cancer treatments or simple lifestyle interventions, are based on foundational science and lots of planning.
Welsh Gender Service surgical referrals paused for clinical review
Data suggests "significantly higher" rates of referral for gender-affirming surgery compared with English services, according to the health board.
Statins can safely cut risk of heart attacks or strokes in healthy people aged over 70, world-first clinical trial shows
Australian-led trial finds low risk of side effects from common cholesterol-lowering medication for otherwise healthy older people
Digital technologies reshape clinical research and public health
JMIR Publications this week released seven feature News and Perspectives articles covering how digital tools are transforming clinical research, public health readiness, health care institutions, and consumer choices.
Mission Health, Monarch, Gurwin Execs Weigh In on Hiring Drivers in the Nursing Home Sector
Survey changes, value-based care and other regulatory updates are shaping how operators hire and build clinical teams. As regulatory priorities shift and
Augusta Health Celebrates Five Years in Mayo Clinic Care Network
Membership brings leading clinical expertise and resources closer to patients in the community. FISHERSVILLE, VIRGINIA — Augusta Health is celebrating five years as a member of the Mayo Clinic Care Network, a select group of independent healthcare providers with access to Mayo Clinic’s knowledge, expertise, and resources. Through the membership, Augusta Health physicians, advanced practice […]
The US switch in shingles vaccines revealed an unexpected heart health pattern
In a natural experiment involving 72,920 propensity-matched US adults aged 60 years and older, recombinant shingles vaccination was associated with a 9% lower cardiovascular disease burden over seven years compared with the live attenuated vaccine. Lower burdens of ischemic heart disease and heart failure were seen in both sexes, while ischemic stroke was significantly lower only among men, supporting further clinical trials and mechanistic studies
Dolly’s generosity to Vanderbilt Health highlighted; reading test results before your doctor has a chance; staying healthy this fall; plus other stories with Vanderbilt Health sources
Dolly Parton’s generosity to Vanderbilt Health was mentioned in many of her obituaries. A sampling: The New York Times, the BBC, NPR, NBC News, The Guardian, and Scripps News. Vanderbilt Health News posted a tribute to her, as well, and Mark Denison, MD, Professor Emeritus of Pediatrics and former director of the Division of Pediatric Infectious Diseases, spoke to NewsNation for a story about her impact on his research. Everyday Health interviewed Trent Rosenbloom, MD, MPH, Professor of Biomedical Informatics, for a story about a new JAMA study that found two-thirds of patients read test results before connecting with a doctor. Comprehension of test results varied: 6.6 percent said they had a poor understanding, 26.8 percent understood the results fairly well, 31.7 percent understood them well, and 34.9 percent understood the results very well. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Healthline (cyclosporiasis cases now in 47 states); “The Naked Scientists” podcast (salmonella outbreak sickens hundreds); Medscape (the lighter-than-usual just-completed Australian flu season); and People (how to stay healthy this fall). Scripps News interviewed Jessica Young, MD, Associate Professor of Clinical Obstetrics and Gynecology, about Vanderbilt researchers launching a study to determine if GLP-1 drugs can help people with opioid use disorder. WSMV Channel 4 News reporter Diana Rocco interviewed Kashish Goel, MBBS, Associate Professor of Medicine and Director of Transcatheter Heart Valve Interventions, for a story about patient Dixie Watt and her minimally invasive valve replacement with the M3 device, the first Food and Drug Administration-approved transseptal transcatheter mitral valve replacement. Fogarty International Center writer/editor Susan Scutti interviewed John Koethe, MD, Associate Professor of Medicine, Division of Infectious Disease, for a profile article for their newsletter, Global Health Matters. The article presents him as an example of a Fogarty Fellow success story and focus on his past and present research, including the HIV/AIDS research he conducted for his Fogarty project at the Centre for Infectious Diseases Research in Zambia in 2008 and 2009.
How A Tribal Health System Built A Wastewater Early-Warning System From Scratch
Tribal health org in remote Alaska proved wastewater surveillance can detect flu, RSV, and COVID-19 days before clinical cases in underserved communities.
Is the keto diet better than the Mediterranean? New clinical trial reveals health benefits
In a clinical trial, people with obesity saw clear health benefits on the keto diet that they didn’t see on two other popular eating regimens
CRF Announces Late-Breaking Clinical Trials and Science to Be Presented at TCT 2026
The Cardiovascular Research Foundation (CRF) announced the late-breaking clinical trials and science selected for presentation at TCT 2026, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. This year’s conference will take place October 31–November 3 at the San Diego Convention Center bringing together leading investigators, clinicians, and innovators from around the world.
Caregiver Mental Health Tied to Mental and Behavioral Health in Youth With Cystic Fibrosis
Clinically significant mental and behavioral health symptoms remain common among youth with cystic fibrosis and their caregivers despite highly effective modulator therapy, a study finds.
The Global Brain Care Coalition: A Model to Put Brain Science into Action
It takes an average of 17 years for a scientific discovery to travel from the lab to clinical practice. In brain health, that delay has a real cost as the globa
Exclusive: Onos Health raises $17M Series A for clinical intelligence
The company expects to raise $25 million to $40 million in a Series B round in the next 18 months.
How IHH Healthcare CEO Prem Kumar Nair is planning for a longer-lived Asia
The head of Asia’s largest private health group is advancing clinical longevity, cancer care, AI and neighborhood-based treatment.
A new cancer vaccine may keep melanoma from coming back
A personalized mRNA vaccine paired with Keytruda may help keep skin cancer from returning after surgery, a large clinical trial suggests.
Coating stops tooth decay in children
A clinical trial found that a topical treatment called silver diamine fluoride stops cavities in young children from getting worse.
Penn State CTSI releases 5-year impact report
For many communities across Pennsylvania, persistent challenges in access to care, chronic disease burden and health equity remain significant hurdles. Over the past five years, Penn State Clinical and Translational Science Institute has worked to bridge this gap with scientific discoveries that don't just stay in the lab, but are translated into real-world, sustainable health solutions.
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update
Clinical Development Strategy for Alzheimer’s Disease Remains the Focus as Anavex Advances Regulatory Progress Across All Three Programs Anavex Submits Completed Alzheimer’s Disease Clinical Study Data and Rett Syndrome Formal Meeting Request to FDA, with an IND Submission for Fragile X Syndrome Planned for September NEW YORK, NY, August 25, 2026 – Anavex Life Sciences […]
PLT Health Solutions Brings Its Clinically Supported Branded Ingredient Platform to Vitafoods Asia
PLT Health Solutions, Inc. will exhibit for the first time at Vitafoods Asia, 2-4 September in Bangkok, Thailand, bringing its portfolio of more than 30 clinically supported branded ingredients to Asian brand owners and product developers. A major focus at the show will be the company's joint health and mobility portfolio. PLT will bring next-generation Kinexa™ Joint Longevity Complex to the Asian market for the first time. PLT introduced Kinexa™ in 2016 and has continued to develop the ingredie
LCMC Health expands cancer services with bone marrow transplant clinic, clinical trials
LCMC recently completed an expansion that is growing its cancer services offerings for patients in New Orleans, poising the health system to better compete against Ochsner Health for cancer patients in the area.
Mozambique strengthens regulation of medicines and imported vaccines, boosting health protection
Mozambique has reached a major milestone in strengthening the regulation of medicines and imported vaccines, with its national regulatory authority recognized by the World Health Organization (WHO) as having a stable, well-functioning and integrated regulatory system.The Autoridade Nacional Reguladora de Medicamentos de Moçambique (ANARME) has achieved Maturity Level 3 (ML3) for the regulation of medicines and imported vaccines under WHO’s global classification of national regulatory authorities.Mozambique becomes the 10th country in Africa to reach ML3, joining Egypt, Ethiopia, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania and Zimbabwe and marking further momentum in strengthening regulatory systems across the region.For people in Mozambique, stronger regulation means greater assurance that medicines and vaccines are appropriately evaluated for quality, safety and efficacy and monitored throughout their lifecycle. It also strengthens the country’s ability to identify and respond to safety concerns and substandard or falsified products, while supporting timely access to quality-assured health products.“Mozambique’s achievement is the result of sustained investment in regulatory capacity that will deliver crucial benefits for public health,” said Dr Sylvie Briand, WHO Chief Scientist and Assistant Director-General a.i. for Health Systems, Access and Data. “Strong regulatory systems protect people, build confidence in health products and help countries respond more effectively to evolving public health needs and challenges. Mozambique’s progress also contributes to advancing regulatory capacity across Africa and promoting more equitable access to safe and quality-assured medicines and vaccines.”Building a stronger regulatory systemMozambique’s achievement follows years of sustained efforts to build the institutions and capabilities needed for effective regulation.WHO worked closely with ANARME throughout this process, assessing the national regulatory system and supporting the authority in addressing identified gaps and strengthening priority areas.WHO evaluates national regulatory systems using its Global Benchmarking Tool (GBT), which assesses the regulatory functions required to ensure the quality, safety and efficacy of medical products. These include registration and marketing authorization, licensing, market surveillance and control, pharmacovigilance, regulatory inspection, laboratory testing and oversight of clinical trials, as applicable. WHO’s maturity levels range from 1 to 4. Reaching ML3 confirms a stable, well-functioning and integrated regulatory system, while ML4 represents an advanced system focused on continuous improvement.Benefits for Mozambique and the African continentAn ML3 regulatory system can support more timely and predictable regulatory decisions, reinforce safety monitoring and help ensure that health products entering and remaining on the market meet appropriate standards.It also creates greater opportunities for regulatory cooperation and reliance – approaches that help authorities make use of the work and decisions of trusted regulators, reduce unnecessary duplication and allocate limited resources more efficiently, while maintaining rigorous standards for quality, safety and efficacy.As the first Portuguese-speaking country in Africa to reach ML3, Mozambique’s experience can also contribute to strengthening regulatory systems and fostering greater cooperation, knowledge sharing and reliance among Portuguese-speaking countries and across the African continent. Its achievement further reinforces a more connected African regulatory ecosystem, providing a solid foundation on which the newly established African Medicines Agency can build to advance regulatory convergence and cooperation across the region.Strengthening confidence in regulatory recognitionMozambique’s achievement comes as WHO strengthens the process through which the performance of national regulatory systems is recognized.The newly established Technical Advisory Group on Regulatory Systems Strengthening (TAG-RSS) brings together independent international experts to advise WHO on whether recommendations concerning regulatory authorities reaching ML3 and ML4 and WHO-Listed Authorities, are supported by the findings of WHO evaluation processes. Its recommendations provide an additional level of independent assurance, strengthening the impartiality, transparency and credibility of WHO’s recognition process.Mozambique is among the first countries to achieve ML3 following consideration and recommendation by the TAG-RSS. As part of the same TAG-RSS process, South Africa was recommended to retain its ML3 status for the regulation of vaccines manufactured, imported or distributed in the country, following an additional WHO assessment. This extends the recognition first granted in 2022 and underscores the sustained performance of the South African Health Products Regulatory Authority (SAHPRA).The two recognitions highlight continued progress in strengthening regulatory systems across Africa, as well as the importance of continued performance, improvement and assessment in sustaining regulatory maturity.WHO will continue working with ANARME and SAHPRA to sustain these gains and support continuous improvement as science, technologies and public health needs evolve.
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today...
The company selling a $3,000 mattress cover that billionaires love wants to become a healthcare company that treats sleep apnea
Eight Sleep wants to turn its consumer sleep data into a healthcare business, but first it has to clear regulatory and clinical hurdles.
You want to join a clinical trial. Here’s what to know about the hurdles.
Connecting people with clinical trials is complicated — even if people identify a promising match, there’s a slew of potentially thorny factors, including geographic incompatibility, and financial and time considerations.
Seattle Children’s names new CIO
Dr. Natalie Pageler has been appointed senior VP and chief information officer after years spent as a pediatrician and clinical informaticist at Stanford Children’s Health and Stanford University School of Medicine.
How to integrate AI into cardiac imaging workflows
Implementing advanced AI models into daily practice takes much more than simply installing software. It requires a clinical champion and multiple stakeholders to coordinate the effort.
HHS announces addition of behavioral health programs eligible for federal reimbursement
The Department of Health and Human Services Aug. 18 announced that its Administration for Children and Families has added two new peer support programs to the Title IV-E Prevention Services Clearinghouse, allowing all states to claim federal reimbursement. One addition is the Family-Based Recovery program, which focuses on in-home clinical treatment for parents combatting addiction who have children ages 0-5.
Oracle Health Expands Clinical AI Agent with Automated Coding, Dictation, and Chart Review
/PRNewswire/ -- Oracle Health today announced new capabilities for Oracle Health Clinical AI Agent, now available in the U.S., that expand AI across clinical...
Study finds sustained benefit for people using Oregon psilocybin services
OHSU-led research is the largest study of psychedelics outside clinical trials.
Radiology Partners petitions FDA for greater clarity around imaging AI regulations
Mosaic Clinical Technologies believes diagnostic imaging vision-language models represent an “important and promising” advancement in medicine, but one that requires greater regulatory scrutiny.
Could GLP-1s help treat opioid use disorder? Vanderbilt Health study now enrolling
The study, Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB), is a double-blind, randomized, placebo-controlled trial conducted through the National Institute on Drug Abuse’s Clinical Trials Network.
A Veteran and VA social worker’s case for VA Health Chat
Erin Lovinus, Army Veteran and VA clinical social worker, uses VA Health Chat as part of her VA healthcare and recommends the app to others as well.
Not every elite sports innovation belongs in your routine
Adam Annaccone, clinical associate professor of kinesiology, explains why not every cutting-edge athletic innovation belongs in a daily health routine
Artificial Intelligence helps Munson health care provider focus more on patients, less on screens
FORT LEAVENWORTH, Kansas — For Mikaela Altis, a physician assistant in Munson Army Health Center’s Department of Primary Care, adopting ambient listening technology has meant more eye contact with patients, more time for follow-up questions and fewer hours spent completing clinical notes after the workday ends.
Low-fat vegan diet helps people lose weight without eating less
A low-fat vegan diet may help people lose weight without counting calories, shrinking portions, or feeling constantly hungry. In a 16-week clinical trial, people eating mostly fruits, vegetables, grains, and legumes consumed about 357 fewer calories per day even though the total amount of food they ate barely changed.
Wildfire smoke may be hurting Iowans' physical and mental health
Even with all the recent rain, much of Iowa’s northern half remains under a moderate health advisory due to smoke from distant wildfires, and a mental health expert says that smoke is affecting more than just people’s lungs. Clinical health psychologist Dr. Kristi White says many of her patients are bringing up the smoky conditions […]
ANTHC partners with UAA to offer local clinical rotations for healthcare students
Dr. Jay Butler, dean of the UAA College of Health, said the partnership will keep local students from leaving the state for clinical rotations.
You want to join a clinical trial. What to know about the hurdles
HHS began an effort to streamline clinical research, and legislation is pending in Congress. But patients and providers face participation challenges.
In a Heartbeat: Navigating the intersection of AI and personal healthcare
The use of artificial intelligence is becoming ubiquitous, but when it comes to health care, determining when and where organic intelligence should drive action could be a lifesaving distinction. Dr. Jose Francisco Abad, a family medicine physician and certified clinical informatics specialist guiding AI implementation at UPMC, recently parsed the
Medicare approves new technology add-on payment for inpatient radiology AI solution
The federal insurance program for seniors will pay a maximum of $137.53 per case for Aidoc's CARE (Clinical AI Reasoning Engine) Multi-Triage CT Body tool.
MVNU launches online Master of Science in Speech-Language Pathology
MOUNT VERNON — Mount Vernon Nazarene University has launched its Master of Science in Speech-Language Pathology (MS-SLP), a graduate program featuring fully online coursework and extensive clinical training to prepare the next generation of skilled speech-language pathologists. Offered through MVNU’s College of Adult and Professional Studies, the program prepares students to diagnose and treat a […]
UNT Health Fort Worth expects nearly flat revenue, higher spending in 2027
The university expects a small revenue increase and raises expenditures $8.2 million as it pursues enrollment, research and clinical growth.
AI needs science’s search history
“Actually, that’s where the gold is,” said Alasdair Russell, my graduate school friend who leads a pre-clinical genome editing group at Cambridge. He was talking about the winding road of science that is omitted from published papers. “When you’re discussing how to do the experiment, and why this way is better than another way, and what does the data really mean? I know what it shows, but what does it mean?” At RAAIS 2026, he described how his group has begun logging the twisting path of discovery as it happens, recording the verbal and written exchanges that normally disappear. Ideas become nodes in a living graph: they branch when a meeting produces two plausible experiments, merge when separate lines of evidence converge, and go dark when someone quietly stops pursuing them. In his implementation, one agent scores novelty, while another tries to learn “how scientists think and how they navigate through a complex world of data,” so that high-potential nodes can trigger deeper investigation. As frontier AI labs deploy agents toward scientific discovery, giving AI authentic scientific taste remains a trillion-dollar dilemma. The bottleneck is that the record we have kept for centuries of science might be insufficient to get us there. The experiments that never make the paper Peter Medawar, 1960 Nobel laureate and “father of transplantation,” asked in 1963 whether the scientific paper was a fraud, and answered yes: the form of the paper misrepresents the thinking that produced it. Sixty years on, the diagnosis is unchanged. A paper presents a clean progression from hypothesis to result to conclusion. Lost along the way are the unconventional theories, the abandoned or unaffordable methods, and the underwhelming and inconclusive data. It reads like a browser history with every dead end deleted: the ten open tabs, the four rephrased queries, the wrong turn down a subforum. All scrubbed, leaving one clean path from question to answer as the canonical path. What has changed since then is that the discarded material is now worth something. No high-impact journal wants these artifacts, but raw trial and error is the most likely source of the training data required to develop scientific intuition, or what researchers call taste. Earlier attempts to capture the discards were motivated by scientific integrity. The Journal of Negative Results in Biomedicine launched in 2002 to publish rigorous studies that disputed established models or exposed ineffective treatments. Its archive preserved negative conclusions after they had become papers, rather than the live alternatives and arguments that produced them. BioMed Central closed it in 2017, saying the mission had been served now that other journals publish null results. A less generous reading is that in fifteen years it published around 200 papers because almost nobody wants to read a negative result, let alone write one up when it will not count toward academic tenure. AI models are different. Even an uninteresting negative result can be useful, provided it is labeled. Earlier this year, Anthropic put a version of this to the test. The company pulled 129 decision points from real Claude Code sessions between January and March 2026, showed models the work up to a human detour, and asked what should happen next. Claude Mythos Preview beat the human choice 64% of the time, while Opus 4.5 managed 51%. The comparison was tilted toward the models because Anthropic deliberately chose moments where the human decision had room for improvement. On 127 further scenarios where the human action was already strong, the models improved on it only about 20% of the time. The study was possible because Anthropic’s researchers work inside a tool that logs by default. The reasoning, detours and outcome are produced in the same working environment. Biology has no equivalent. Its reasoning happens in hallways, at benches, in Slack threads and on whiteboards, while the outcome arrives weeks later somewhere else. The record has to emerge from the work itself. Ask scientists to reconstruct it afterwards and we’ll create another polished account. Subscribe A log is not a label Before any of this becomes training data, a negative result has to say what failed. The first paper published in the Journal of Negative Results in Biomedicine examined 234 negative studies across five leading medical journals. Only 30% discussed statistical power, and half clearly defined a primary outcome. Tell a model an experiment failed, without telling it whether the assay was underpowered, a reagent had degraded, or the hypothesis was simply wrong, and it will learn noise with confidence. Decision histories have a second missing label too. When a lab considers five experiments and runs one, only the chosen branch returns an outcome. The other four are experimental counterfactuals. Researchers call this the selective labels problem: the data reveal results only for the actions someone chose to take. Such a record can teach a model to imitate a lab’s taste, but it cannot establish that the taste was good. It also smuggles local constraints into general lessons. A lab that never ran cryo-EM because it did not own a microscope teaches a model that cryo-EM is rarely the right call. Alasdair’s nodes preserve the candidate set, which is the necessary first step. To be useful, each decision record needs six fields: The evidence available at that moment, and nothing that arrived later. The candidates considered, including the ones dismissed in a sentence. For each candidate: the expected result, the confidence attached to it, and the cost in time and money. The route chosen, and the reason. What happened next. How the evidence changed the scientist’s view. These must be timestamped before the outcome, because hindsight turns uncertainty into inevitability. Disagreement also has to survive. Averaging three scientists into one clean rationale reproduces exactly the information loss we are trying to fix. But there is an obvious failure mode here. Once decisions are logged and scored, people log for the record post-facto. Anyone who has watched an electronic lab notebook fill up with retrospective tidying knows how quickly a research tool becomes a compliance exercise. A record that costs a scientist ten minutes of honest reflection per decision is worth far more than one that costs an hour of performance. A publication initiative called Registered Reports offers a useful starting point. Here, researchers submit their rationale, methods and analysis plan for peer review before the data exist, and the journal commits in principle to publish if they follow the approved plan. Nature has now expanded the format across every field it covers. This approach to paper writing timestamps intent before the outcome, but it freezes one plan. A useful search history must also preserve how the plan changed, which alternatives were rejected, when, and on what evidence. Subscribe Run the runner-up Autonomous labs show what happens when decisions and outcomes are connected in a loop. Liverpool’s mobile robotic chemist ran 688 experiments over eight days in a ten-variable formulation space. A batched Bayesian search used each result to choose the next experiments and found photocatalyst mixtures six times more active than the starting formulations. Every completed experiment changed what the system did next. The robot optimized within a goal and search space that humans had already chosen. It did not decide which scientific question mattered. So what this work demonstrates is narrower, but still useful: a search history pays off when the options return standardized outcomes quickly. Open-ended biology is harder because branches can take weeks and the discarded alternatives may never be run. Some exploration therefore has to be bought. Where two branches are plausible and the stakes justify the cost, a lab should sometimes run the runner-up. Otherwise the record captures what today’s scientists usually chose and stays silent on what they systematically overlooked. A funder could ring-fence a small fraction of a grant for the branch not taken, provided that the decision record and the outcome are both deposited. That costs money, but so does having every lab rediscover the same abandoned path. Test whether taste transfers When it comes time to evaluate if our new AI system exhibits taste, the comparison should run across laboratories and fields. At selected decision points in a live research campaign, we should freeze the six fields: the evidence, the candidates, expected results, confidence, costs and the choice made. Experts then rank the options before the outcomes are known, and those outcomes are checked independently later. We could give models one of two diets - papers alone, or papers plus decision histories - and ask them to rank the next experiment on unfamiliar projects. Then, we score information gained per dollar and week, calibration, and how quickly weak branches are abandoned. If histories improve choices only inside the lab that produced them, they amount to useful organizational memory. If they improve choices on unfamiliar problems elsewhere, Alasdair’s group will have captured something science has never managed to write down: a transferable record of taste. Until that happens, a scientific search history is a promising record, not yet a training set.
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
/PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative...
Intermountain Health Names Veteran Leader as New Peaks Region President
Intermountain Health has selected Scott Peek as the new region president to oversee business and clinical operations across the enterprise’s markets in Colorado, Montana, Eastern Wyoming, and New Mexico, known as the Peaks Region. Most recently Peek has served as the operational lead for the region and as the market president for the Colorado ...
MVP leads to health discoveries for Veterans like you
Research findings from VA’s MVP are helping move discoveries toward use in clinical care, improving health and wellness for all Veterans.
Northwestern earns CACREP accreditation for clinical mental health counseling
Northwestern College’s master’s program in clinical mental health counseling has received accreditation from the Council for Accreditation of Counseling and Related Educational Programs (CACREP), the premier nationally recognized accrediting organization for counseling education programs.
Factors that make radiologists less likely to be fooled by large language models
Successful radiologist-LLM collaboration depends on confidence in the AI model, along with the reader possessing key clinical expertise, according to new research.
Samsung is Starting to Catch Up to Apple on Hearing Health
Samsung today said its Galaxy Buds Hearing Aid feature has been cleared by the U.S. FDA, which means hearing aid capabilities will be coming to the Galaxy Buds in the fourth quarter of 2026. Samsung will join Apple in offering over-the-counter hearing aid functionality. Apple added an FDA-cleared hearing health feature to the AirPods back in 2024, allowing them to be used as a clinical-grade hearing aid.
As Candida auris spreads, UT Health San Antonio scientist highlights growing threat of antifungal resistance
Life-threatening fungus now in 27 states; Texas with second-most clinical cases Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu Content provided by Claire Kowalick SAN ANTONIO, Aug. 11, 2026 – As cases of the potentially deadly drug-resistant fungal infection Candida auris have spread to 27 states, including Texas with the second-highest number, a scientist at UT Health […]
Campbell unites pharmaceutical science, clinical research in future-focused degree
The reimagined bachelor’s program prepares students for careers across the entire drug development lifecycle, with an emphasis on hands-on experience… More on this post
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the...
Formulogic Debuts in Singapore with Science-Driven Barrier Care for Southeast Asia's Sensitive Skin
Formulogic, a science- and evidence-driven dermocosmetic brand dedicated to sensitive skin, developed through dermatological research and clinical validation, officially debuted in Singapore at CONNEX-C Asia 2026, jointly organized by Society of Cosmetic Scientists (Singapore) (SCSS) and Lee Kong Chian School of Medicine, unveiling its evidence-based barrier care philosophy and a comprehensive skincare system designed specifically for Southeast Asia's unique climate and skin concerns.
Nurses seek a seat at the table as they fight expanding clinical AI
Nurses, who make up the largest part of the health care workforce, say clinical artificial intelligence poses a threat to their jobs, and patients.
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Nature Medicine Just Published the AI Mental Health Audit Framework the FDA Hasn’t Written Yet
Nature Medicine's clinically validated AI chatbot audit framework arrives as FDA still lacks generative AI mental health approval standards—here's what trial…
Black Book: Australia's 2027 Health IT Market Shifts From Pilots to Proof
Post-HIC 2026, provider study finds interoperability, clinical cyber continuity and statewide EHR execution will dominate the next buying cycle NORTH SYDNEY, AU / ACCESS Newswire / August 9, 2026 / Black Book Research today announced the publication ...
David Sinclair Launches Lifespan Media Platform for Longevity Science
David Sinclair launches Lifespan media platform to improve public understanding of longevity science research and clinical trials.
Deputies shoot armed person ‘experiencing a mental health episode,’ Riverside County Sheriff’s Office says
Deputies shot an armed person “experiencing a mental health episode” in Moreno Valley Friday, according to the Riverside County Sheriff’s Office. Sheriff’s deputies and a clinical therapist from th…
St. Petersburg psychologist shares advice for long-term health improvements
Clinical psychologist Dr. Elizabeth Bendick in St. Petersburg emphasizes that improving overall health begins with establishing consistent daily habits rather than overwhelming life overhauls.
Tashiba Williams: How Mobile Wound Care Is Expanding Healthcare Access
As a family nurse practitioner and the founder of ADA Family Health Clinic, a mobile wound care and primary care practice serving patients across Texas and Louisiana, Williams represents healthcare professionals whose clinical experience may contribute to leadership and care-delivery discussions.
How Cohere Health digitizes clinical policies using Amazon Bedrock AgentCore
In this post, you learn how Cohere Health built a multi-tenant agentic architecture on AgentCore using AgentCore Runtime’s secure MicroVM isolation, unified tool access through AgentCore Gateway, AgentCore Memory, and the Agent Skills open standard to rapidly scale policy digitization capabilities, while preserving transparency, version control, and human oversight.
A clinically validated framework for auditing AI chatbot behavior in mental health interactions
Nature Medicine - Across 810 conversations, an evaluation framework finds that AI chatbots often amplify simulated users’ psychological vulnerabilities, revealing persistent safety risks in...
New heart drug targeting inflammation falls short in clinical trial
The ZEUS trial fell short, but Novo Nordisk still has high hopes for HERMES and ARTEMIS.
US Stand Up for Science movement expands to Europe
A grassroots movement by scientists in the US pushing back against threats to academic freedom is setting up a Swiss outpost to take the movement global. Stand Up for Science started in February 2025 to protest against politically-motivated grant cancellations by the Trump administration. Since then, it has organised numerous rallies by scientists and turned into a broader campaigning organisation, supporting “pro-science” political candidates and attempting to impeach Robert F. Kennedy Jr, the health and human services secretary the group accuses of advancing “quack” science. Now, Stand Up for Science is establishing a Swiss office to take some of its campaigning beyond the US, and its leader is urging European academics to organise similar pro-science groups in case they face similar threats in Europe. There will likely be “spillover” to Europe from what the Trump administration is attempting in the US, said Colette Delawalla, chief executive of Stand Up for Science, who last month returned from a tour of Europe. “Are we going to see a Trump-style scientific [. . .] take over in the same way?” she asked.Delawalla, who is doing a PhD in clinical psychology, said she was driven to help found the organisation after the Trump administration started cancelling health research grants in politically taboo topics, such as transgender people, diversity and HIV, in early 2025. Since then, the administration has introduced several other measures that infringe academic and institutional autonomy.It threatened to cut Harvard University’s federal funding unless the university accepted a “critical mass” of new faculty and students to create “viewpoint diversity.” And this year, it proposed explosive new rules that would allow political appointees at research funders to screen grants to make sure they “advance the president's policy priorities.”US scientists have been at times stunned by the volume of announcements, and the country’s researchers were relatively unprepared. “We sit in front of the fire hose every day,” said Delawalla. For this reason, European scientists need to prepare now for similar assaults. “If you've got a little bit of extra time to start thinking through, and making those preparations and building community and solidarity,” then European researchers will “start five steps ahead of where we were.” She plans to return to Paris in September to share experiences with concerned French academics. Is Le Pen the same?During her European tour, Delawalla said that French academics were beginning to worry about a National Rally (RN) victory in presidential elections next year. She said there were “chilling similarities” between Trump and Marine Le Pen, the RN’s likely candidate. However, so far, the RN hasn’t proposed anything nearly as radical as the Trump administration has carried out. Its current manifesto is all but silent on university and research policy. Le Pen’s 2022 manifesto bemoaned a lack of French R&D spending, including in fundamental research, and promised to modernise labs and strip away grant bureaucracy. The party’s 2024 European election manifesto explicitly supported the Erasmus+ student exchange programme, scientific exchange and joint European technology projects. However, a Le Pen victory next year could see France drastically cut its contribution to the EU, which would hit the budget for science and innovation. Meanwhile, more restrictive immigration policies could hit university recruitment of faculty and students. Climate science denial?As heatwaves and wildfires have ravaged France, the RN has sought to distance itself from previous comments casting doubt on climate science.In the UK, the radical-right party Reform UK, now second in the polls, denied climate research in a draft of its 2024 election manifesto, but its leader, Nigel Farage, then appeared to quietly U-turn and said he was “not arguing the science.” By contrast, Trump has repeatedly and explicitly denied climate change science, in 2025 calling it “the greatest con job.” Like the RN, Reform UK has been light on research and university policy. However, it did say in its 2024 manifesto that universities should suffer “heavy financial penalties” for allowing “political bias or cancel culture” on campus, building on laws brought in by a previous Conservative government. Ahead of September state elections in Saxony-Anhalt in Germany, the poll-leading Alternative for Germany has proposed abolishing gender studies and postcolonial studies, and promised money for “critical” climate research and studies of Islam. Starts with rhetoricEven if European radical right parties aren’t currently planning the draconian policy measures of the Trump administration, Delawalla said that academics should not be complacent, and fight even small funding restrictions or anti-science talk from the start. “It starts off with sowing distrust about institutions,” she said. “It starts off with these small things, and then all of a sudden it's there.” There are other, more established science and university advocacy groups in the US aside from Stand Up for Science. But the group stands out because of Delawalla’s refusal to attempt to appear politically bipartisan or conciliatory. “I firmly believe that the US is experiencing fascism,” she said. “We’re not trying to win over the super Maga people,” she said, “and we never have been.” The lesson of the US is that even if universities or other institutions capitulate to government demands, this doesn’t save them from cuts and restrictions. “It doesn’t matter what people do,” she said. Global “pseudoscience”Another aim of Stand Up for Science’s push into Europe is to better coordinate a campaign to protect people in poorer countries from what the group describes as “pseudoscientific exploitation,” trials outside the US used to build a case against things like vaccines. Earlier this year, the group sent an investigator to Guinea-Bissau to investigate a controversial, Danish-run Hepatitis B vaccine project funded by the US Centers for Disease Control and Prevention.The study would have withheld a proven vaccine from newborns, Stand Up for Science argued in a briefing it presented to Congress, risking their health. Significantly, the research group based in Guinea-Bissau, known as Bandim, focuses on the “non-specific effects” of vaccines: impacts on health beyond preventing the target disease. Related articlesEuropean researchers sound the alarm that Trump rule changes will hit cooperationData corner: which fields of health science is the US curbing? The US ‘golden age’ science strategy: what Europeans need to know The suspicion is that the study was funded as part of an attempt to shop around for results that could help build a case against vaccines in the US, said Delawalla. “This is just code for vaccines cause autism,” she said.Bandim has put out a rebuttal of Stand Up for Science’s criticisms, arguing its work has uncovered a number of vaccine side effects, both positive and negative, which need to be taken into account in public health. However, Congressional Democrats took up the Stand Up for Science cause, and in February, Guinea-Bissau said it had permanently halted the study. WatchdogBut for Delawalla, this is not the end of the fight. Kennedy has made a number of health claims that scientists think lack evidence, such as the idea that seed oils cause inflammation, for example. Delawalla worries that more studies could be launched in poorer countries to fish around for evidence to support this agenda. Stand Up for Science is talking to African science organisations to create a kind of “watchdog” to scrutinise any further trials. “Outsourcing the investigation to some of the most vulnerable children in the world who are desperate [. . .] is fundamentally wrong,” she said.
Experts share MRI efficiency strategies that could raise revenue by upward of 60%
Workflow redesigns have the potential to improve MRI throughput by 20%, while AI-based protocol optimization could boost efficiencies by another 35%, experts write in Clinical Imaging.